Supplementary Figure S10 from Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity
Year: 2026
Type: supplementary-materials
Abstract: Relative proteasome activity in iTEX treated with bortezomib, relative T-cell survival following bortezomib exposure, correlation between T-cell viability and proteasome activity under different doses of bortezomib, and the cytotoxic capacity of hCD19-CAR iTEX in the presence of bortezomib against SK-MEL-28 cells engineered to overexpress hCD19.
Authors: Ander de Blas, Massimo Andreatta, Asier Antoñana-Vildosola, Paloma Velasco-Beltrán, Leire Egia-Mendikute, Borja Jiménez-Lasheras, Alexandre Bosch, Adrián Barreira-Manrique, Iker Oyenarte, So Young Lee, Christoph Heuser-Loy, Jeremy G. Baldwin, Roland C. Schelker, Azucena Martín-Santos, Fabio Mastrogiovanni, Mikel Azkargorta, Felix Elortza, James D. Sutherland, Veronica Torrano, Ana M. Aransay, Lorena Pérez-Gutiérrez, Alena Gros, Santiago J. Carmona, Luca Gattinoni, June Ereño-Orbea, Endika Prieto-Fernández, Asis Palazon
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7164840064